Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Clinical Trials Market Size Worth $65.2 Billion by 2025 | CAGR: 5.7%: Grand View Research, Inc.

Grand View Research,Inc.
Posted on: 16 Aug 17
Clinical Trials Market Size Worth $65.2 Billion by 2025 | CAGR: 5.7%: Grand View Research, Inc.

PR Newswire

SAN FRANCISCO, August 16, 2017

SAN FRANCISCO, August 16, 2017 /PRNewswire/ --

The global clinical trials market is expected to reach USD 65.2 billion by 2025, according to a new report by Grand View Research, Inc. Key drivers impacting the market growth are globalization of clinical trials, development of new treatments such as personalized medicine, augmenting evolution in technology, and boosting demand for CROs to conduct clinical trials.

     (Photo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )
Globalization of clinical trial has led to increase in investment in new product development in emerging countries thereby, having a positive impact on overall market. The availability of the vast array of services from drug discovery to post-marketing surveillance has further simplified the life for mid-size and small-scale pharmaceutical and biotechnological organizations by providing them the option to outsource what they think is beyond their core expertise. For instance, Pfizer currently has three CROs working with it to enhance its product portfolio and drive innovation. According to the partnership agreement with ICON in 2011, Pfizer would only preserve the scientific ownership for the trials and studies conducted by ICON, hence allowing the company to focus and further develop its capabilities in clinical trial designing.

Growing prevalence of disease and incidence of new disease is expected to give further boost to the clinical trial market. Worldwide population has varied disease profile with emerging countries having the most diverse disease profile. This is expected to boost the clinical trial of new or rare disease which otherwise would not have found any sponsors. More number of patients having a specific disease would act as a stimulus for biopharmaceutical companies to invest more in clinical trials for a disease segment.

Browse full research report with TOC on " Clinical Trials Market Analysis By Phase (Phase I/II/III/IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Autoimmune, Pain management, Oncology, CNS condition, Diabetes, Obesity), And Segment Forecasts, 2014 - 2025 " at: http://www.grandviewresearch.com / industry-analysis/global-clinical-trials-market

Further key findings from the report suggest: 

  • The global clinical trials market witnessed a lucrative growth in 2016 and is expected to grow at a CAGR of over 5.5% from 2017 to 2025
  • The market is expected to be dominated by Phase III as of 2016, with Phase I anticipated to witness the fastest growth
  • Increasing innovation and evolution of treatment is predicted to contribute towards growth of the expanded access trials segment
  • Based on indication, the oncology segment is anticipated to witness the fastest growth. According to various sources, more than USD 38.0 billion is currently being spent by the healthcare industry towards preclinical and clinical development of oncology therapy products
  • North America dominated the overall market in terms of revenue share in 2015 owing to the presence of big outsourcing firms and increasing R&D in the region.
  • Key players including Quintiles IMS, Paraxel International Corporation, Charles River Laboratories, ICON plc, SGS SA among the others dominate the global clinical trials market while representing maximum volume in 2016

Browse related reports by Grand View Research: 

Grand View Research has segmented the global clinical trials market on the basis of phase, study design, indication, and region: 

  • Phase Outlook (Revenue, USD Million; 2014 - 2025)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Study Design Outlook (Revenue, USD Million; 2014 - 2025)
    • Interventional
    • Observational
    • Expanded Access
  • Indication Outlook (Revenue, USD Million; 2014 - 2025)
    • Autoimmune/inflammation
    • Pain management
    • Oncology
    • CNS condition
    • Diabetes
    • Obesity
    • Cardiovascular
  • Regional Outlook (Revenue, USD Million; 2014 - 2025)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • China
      • Japan
    • Latin America
      • Mexico
      • Brazil
    • MEA
      • South Africa

Read Our Blog By Grand View Research : http://www.grandviewresearch . com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com

SOURCE Grand View Research, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 16/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.